RxDoctor Payments Data

Ancy Thomas, NP

Family · Plano, TXNPI 1952877409

Payments from drug & device makers

$5,313in general payments, 2019–2025

Across 245 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$480
  • AstraZeneca$476
  • Merck$408
  • Daiichi Sankyo Inc.$351
  • Pfizer$250
  • Takeda Pharmaceuticals U.S.A., Inc.$222
  • plus $3K from 51 others

What the payments were for

  • Food & beverage$5,293100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson19$480
AstraZeneca(2 entities)16$476
Merck23$408
Daiichi Sankyo Inc.19$351
Pfizer11$250
Takeda Pharmaceuticals U.S.A., Inc.11$222
Jazz Pharmaceuticals Inc.8$200
Incyte Corporation8$173
Tactile Systems Technology Inc3$163
EMD Serono, Inc.6$150
Regeneron Healthcare Solutions, Inc.7$142
Eisai Inc.6$130
Adaptive Biotechnologies Corporation6$128
AbbVie5$125
Bayer6$110
Blueprint Medicines Corporation5$105
Impulse Dynamics (USA) Inc.6$100
Karyopharm Therapeutics Inc.4$88
Lilly USA, LLC4$84
Esperion Therapeutics, Inc.4$81
Dendreon Pharmaceuticals LLC3$81
Kowa Pharmaceuticals America, Inc.6$81
Boehringer Ingelheim4$80
Genmab U.S., Inc.4$76
Geron Corporation3$69
Stemline Therapeutics Inc.3$57
E.r. Squibb & Sons, L.L.C.1$54
Astellas Pharma US Inc3$52
Novartis2$50
Actelion Pharmaceuticals US, Inc.2$50
Servier Pharmaceuticals LLC2$49
Arbor Pharmaceuticals, Inc.3$46
Mirati Therapeutics, Inc.2$44
Springworks Therapeutics, Inc.2$42
Syndax Pharmaceuticals, Inc.2$39
Menarini Silicon Biosystems, Inc.2$35
ADC Therapeutics America, Inc.2$34
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$29
Recordati_rare_diseases_inc.1$27
Amgen1$26
Sanofi1$25
Sobi, Inc1$24
Legend Biotech USA Inc.1$24
Pharmaand GmbH1$23
QOL Medical, LLC1$22
Morphosys, US Inc.1$22
AVEO Pharmaceuticals, Inc.1$22
Seagen Inc.1$20
Ironwood Pharmaceuticals, Inc1$20
Exelixis Inc.1$18
Boston Scientific1$17
Helsinn Therapeutics (U.S.), Inc.1$16
Rigel Pharmaceuticals, Inc.1$16
Caris MPI, Inc.1$16
Genentech USA, Inc.1$15
Iovance Biotherapeutics, Inc.2$13
Novo Nordisk1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,313 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$53,708
Medicare patients
335
Services billed
763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mometasone Furoate11$425
Tamsulosin Hcl31$365
Lorazepam16$13

Paid to pharmacies, not to this prescriber.

Other family in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →